Bernstein Liebhard LLP is investigating whether the Board of Directors of Adolor Corporation (“Adolor” or the “Company”) (NASDAQ: ADLR) breached its fiduciary duty to its shareholders in agreeing to sell Adolor to Cubist Pharmaceuticals, Inc.
Under the terms of the agreement, Adolor shareholders will receive $4.25 in cash for each share they own (plus a Contingent Payment Right). The investigation is focused on the potential unfairness of the price to Adolor shareholders and the process by which the Adolor Board of Directors considered and approved the transaction.
If you are interested in discussing your rights as an Adolor shareholder and/or have information relating to the matter, please contact U. Seth Ottensoser at (877) 779-1414 or Ottensoser@bernlieb.com.
Bernstein Liebhard has pursued hundreds of securities, consumer and shareholder rights cases and recovered almost $3 billion for its clients. It has been named to The National Law Journal’s “Plaintiffs’ Hot List” in each of the last nine years.